Purple Corner Page Header
GMP System


Customized, Modular, Client-specific Scale-up System for cGMP manufacture of Nanoparticles

  • The GMP System can deliver manufacturing volumes in the range of 200 ml to tens of liters. The flexibility and scale in manufacturable volumes is achieved by “scaling out” made possible by arraying multiple microfluidic devices in parallel thus increases volume output without changing manufacturing conditions
  • Fully disposable fluid path components to reduce risk and cost (re: cleaning validation)
  • HPLC pumps designed for ultra-low pulsations in fluid flow. Specifically designed and custom made for the PNI’s system to facilitate access and easy replacement
  • Components made of inert materials (Stainless Steel, PEEK, EPDM, COC) and microfluidic mixer material tested and cleared for extractables
  • Designed to work with downstream processing systems (e.g. Tangential Flow Filtration) in a standard drug product manufacturing workflow

NanoAssemblr GMP System: Is a modular and configurable system, fit-for-purpose and phase appropriate, for the GMP manufacturing of nanomedicines.

Scale-Up System
Polymeric Nanoparticle & Liposome

Flexible, Efficient & Reproducible 

Clinical Development

NanoAssemblr Technology: Ensures that the nanoparticle formation conditions are uniform, controlled and reproducible. Results in faster development times, easier scale up and higher production yields.


连续流动微流控平台专为在 cGMP 条件下扩大纳米颗粒制备规模而设计。


Nanoparticles manufactured on the GMP System are functionally similar to those produced with the NanoAssemblr® Benchtop and Blaze.

制备从  NanoAssemblr® Benchtop 转移到 Scale-Up 系统之后,siRNA 纳米颗粒表现出了相等的粒径大小、多分散性和体内活性。
Scale-Up: Consistent Size
Scale-Up: Consistent Composition
Scale-Up: Consistent Activity



Nucleic Acid Lipid Nanoparticle








Scale-Up Tech: Multiple Cartridges



Multiple microfluidic devices can perform the same operation in parallel to increase throughput. 

Polymeric Nanoparticle










核酸脂质纳米颗粒 (LNP) 制备。缓冲液中的核酸(左)和溶剂中的脂质纳米颗粒前体(右)注入微流控试剂盒的两个入口,两者以可控的方式混合。通过改变相对流速和总流速,可以制备粒径大小不同的脂质纳米颗粒(最右)。

Scale-Up Technology: Formulation


欲了解 Precision NanoSystems 如何加速从创意到临床应用的纳米药物研发过程,请联系我们的技术销售团队。



Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Select...

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. F...

Read More 阅读更多

Publication - Abstract

May 08, 2020


Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner a...

Read More 阅读更多

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to...

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Ro...

Read More 阅读更多

Publication - Abstract

December 31, 2019


Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多

Publication - Abstract

May 31, 2019


mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerate...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith...

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid Nanoparticle-mediated siRNA Delivery for Safe Targeting of Human CML In Vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, M. Heuser et al.

Read More 阅读更多
Resource Center 资源中心